US FDA Grants Fast Track Designation for Paradigm’s Phase 3 Osteoarthritis ProgramFDA Fast Track Designation for Pentosan Polysulfate Sodium (Zilosul™/PPS) offers pathways to expedite development of Paradigm’s osteoarthritis clinicalFDA Fast Track acknowledges osteoarthritis as a serious disease wi.
Approval demonstrates the potential of Zilosul™ to address an unmet medical need in OA which effects more than 72 million people in the US, EU5, and Canada KEY.
An applicant or employee whose COVID-19 results in mild symptoms that resolve in a few weeks with no other consequences will not have a disability that
About 10% of people who contracted COVID-19 continue to suffer persistent symptoms months later, creating the potential for millions of people to suffer